Pfizer Inc. $PFE Shares Purchased by Haverford Trust Co

Key Points

• Haverford Trust Co increased its stake in Pfizer Inc. by 22.3%, acquiring an additional 80,495 shares, bringing its total ownership to 440,875 shares valued at approximately $11.17 million.
• Multiple institutional investors, including Vanguard Group and Northern Trust Corp, have also raised their holdings in Pfizer, which indicates growing institutional interest in the company.
• Despite recent earnings surpassing expectations, several analysts have adjusted their target prices for Pfizer stock downward, with a consensus rating of "Hold" and an average target price of $28.12.

Haverford Trust Co raised its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 22.3% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 440,875 shares of the biopharmaceutical company's stock after acquiring an additional 80,495 shares during the period. Haverford Trust Co's holdings in Pfizer were worth $11,172,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of PFE. Vanguard Group Inc. grew its position in shares of Pfizer by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company's stock valued at $13,257,004,000 after buying an additional 4,629,976 shares during the last quarter. Northern Trust Corp lifted its holdings in shares of Pfizer by 6.8% in the first quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company's stock valued at $1,579,340,000 after purchasing an additional 3,943,397 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Pfizer by 3.5% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 39,402,619 shares of the biopharmaceutical company's stock valued at $1,045,351,000 after buying an additional 1,333,740 shares during the period. Invesco Ltd. increased its position in Pfizer by 2.8% in the first quarter. Invesco Ltd. now owns 30,296,337 shares of the biopharmaceutical company's stock worth $767,709,000 after buying an additional 838,198 shares during the last quarter. Finally, Deutsche Bank AG increased its position in Pfizer by 7.0% in the first quarter. Deutsche Bank AG now owns 28,239,197 shares of the biopharmaceutical company's stock worth $715,581,000 after buying an additional 1,846,436 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

NYSE:PFE traded down $0.73 during mid-day trading on Monday, hitting $25.15. The company's stock had a trading volume of 32,304,503 shares, compared to its average volume of 45,249,543. The business's fifty day moving average is $24.70 and its two-hundred day moving average is $24.39. The stock has a market cap of $142.99 billion, a price-to-earnings ratio of 13.38, a PEG ratio of 0.92 and a beta of 0.52. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter in the prior year, the firm earned $0.60 EPS. The company's revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 6.8%. Pfizer's dividend payout ratio is 91.49%.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on PFE shares. Jefferies Financial Group lifted their price objective on Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research note on Wednesday, May 21st. The Goldman Sachs Group upped their target price on Pfizer from $25.00 to $27.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. HSBC reduced their price objective on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research note on Monday, May 19th. Wolfe Research raised their target price on Pfizer from $22.00 to $23.00 and gave the stock an "underperform" rating in a report on Wednesday, April 30th. Finally, Leerink Partners cut their price objective on Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a research report on Wednesday, April 30th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.